Damon Runyon News

Pardis C. Sabeti, MD, DPhil (Damon Runyon Fellow ‘04-‘06) of Harvard University, Cambridge, will receive the 2017 Richard Lounsbery Award from the National Academy of Sciences. She is recognized for her groundbreaking contributions including the development of new methods to study evolutionary selection in humans and viruses; the creation of new collaborative models for combatting emerging diseases across disciplinary and national borders; and leadership of global efforts to increase data sharing in pandemics such as Ebola and Lassa Fever.

Elaine V. Fuchs, PhD (Damon Runyon Board Member, Damon Runyon Fellow ‘77-‘79) of The Rockefeller University, New York, has been named the recipient of the 2017 McEwen Award for Innovation. The prize, given by the International Society for Stem Cell Research, recognizes groundbreaking work pertaining to stem cells or regenerative medicine. Dr. Fuchs studies adult skin stem cells, how they make and repair tissues, and how cancers develop.

Akinyemi I. Ojesina, MBBS, PhD (Damon Runyon Fellow ’08-’11), of University of Alabama at Birmingham, worked with The Cancer Genome Atlas Research Network to identify novel genomic and molecular characteristics of cervical cancer that will aid in the subclassification of the disease and may help define personalized therapies for each individual patient.

By Ralph Kleiner, PhD, Damon Runyon - Dale F. Frey Breakthrough Scientist; Assistant Professor, Princeton University

As a chemical biologist, my work is motivated by a desire to understand the natural world. While pursuing basic research may seem far removed from the clinic, fundamental advances in our molecular understanding of biology have transformed our ability to diagnose and treat cancer as well as other diseases. Since scientific progress is often slow and can follow a circuitous path, it is absolutely critical that organizations like Damon Runyon are willing to play the ‘long game’, and invest in early stage and basic research.

By Daniel Webster, PhD, Damon Runyon-Philip O’Bryan Montgomery Jr. MD Fellow

The Damon Runyon Cancer Research Foundation recently asked some of our current award recipients how cancer will be prevented, diagnosed, and/or treated differently in the future. What can a future cancer patient, say 10-20 years from now, expect to experience? Their responses were fascinating, and over the next few months we will share their visions for the future on this blog. 

Elaine V. Fuchs, PhD (Damon Runyon Board Member, Damon Runyon Fellow ‘77-‘79) and Shruti Naik, PhD (Damon Runyon Fellow ’14-’18) at The Rockefeller University, New York, and colleagues, found that skin squamous cell carcinomas alter the protein-making machinery to preferentially use tumor-related mRNAs, leading to the production of proteins important for cancer progression. This switch is linked to a ribosome initiation factor called eIF2 and transition initiation factor eIF2A.

Trudy G. Oliver, PhD (Damon Runyon-Rachleff Innovator ’13-’15), and colleagues at the Huntsman Cancer Institute at the University of Utah, Salt Lake City, reported the generation of a new mouse model for studying small cell lung cancer (SCLC). They demonstrated that Myc oncogene expression cooperates with Rb1 and Trp53 loss in the mouse lung to promote aggressive, highly metastatic tumors that are initially sensitive to chemotherapy followed by relapse.

Feng Zhang, PhD (Damon Runyon-Rachleff Innovator ‘12-‘14) of the Broad Institute, Cambridge, and colleagues, reported the discovery of new types of RNA-targeting CRISPR systems, which utilize a novel Cas enzyme called Cas13b. Cas13b is capable of targeting and degrading RNA (rather than DNA, which is targeted by previous CRISPR systems), which will enable researchers to specifically manipulate RNA in a high-throughput manner and manipulate gene function more broadly.

Meet Mark W. ZimmermanMeet Mark W. ZimmermanBy Jean Singer of the Jake Wetchler Foundation

As he battled cancer at age 20, my son Jake Wetchler would often say, “Don’t let the cancer win.”  When he died, his father Jonathan Wetchler and I were determined to keep up the fight. Together, we created The Jake Wetchler Foundation to fund innovative approaches to curing pediatric acute myelogenous leukemia (AML). But we didn’t know how to find the best research to support.

The Damon Runyon Cancer Research Foundation was launched 70 years ago today, with a call over the radio to all Americans.  Damon Runyon, the beloved creator of the Guys & Dolls characters, had died from cancer.  His friend, Walter Winchell, the most famous radio personality of his day, went on air and asked every American to send him their dimes, nickels and pennies to help cure cancer.  They did, and we’ve been making groundbreaking strides against cancer ever since.